| Similar Articles |
|---|
 |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.   |
The Motley Fool
November 10, 2009
Brian Orelli |
Small Acquisitions and the Road to Success Bristol-Myers is taking a different route to bulk up. It announced licensing of a phase 2 rheumatoid arthritis drug, ALD518, from privately held Alder Biopharmaceuticals. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
December 11, 2009
Brian Orelli |
Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
The Motley Fool
June 13, 2008
Brian Orelli |
Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
July 9, 2009
Brian Orelli |
Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable. |
The Motley Fool
June 22, 2011
Brian Orelli |
In-Licensing to the Rescue Abbott's latest deal could help shore things up. |
The Motley Fool
June 15, 2010
Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
The Motley Fool
May 19, 2010
Brian Orelli |
A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis. |
The Motley Fool
June 26, 2009
Brian Orelli |
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
The Motley Fool
October 4, 2007
Brian Orelli |
Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year. |
The Motley Fool
May 11, 2011
Brian Orelli |
Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
The Motley Fool
June 4, 2008
Brian Orelli |
Expanding Possibilities Fail to Expand Rigel's Stock Price Rigel gets positive data on a second indication for its lead drug, R788. |
The Motley Fool
December 27, 2010
Brian Orelli |
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline. |
The Motley Fool
December 15, 2010
Brian Orelli |
Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient. |
The Motley Fool
December 22, 2009
Brian Orelli |
Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
June 17, 2004
Brian Gorman |
Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results. |
The Motley Fool
February 17, 2010
Brian Orelli |
$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%. |
The Motley Fool
June 9, 2010
Brian Orelli |
The Drug Passed, but the Stock Fell? Regeneron only bats .500. |
The Motley Fool
December 14, 2007
Brian Orelli |
An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note. |
The Motley Fool
September 2, 2011
Brian D. Pacampara |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
October 7, 2008
Brian Orelli |
Will a Better Drug Sell Better? Positive trial data isn't enough to significantly boost Johnson & Johnson's Remicade. |
The Motley Fool
February 25, 2008
Brian Orelli |
The Biologic That Keeps on Giving Just a month after Abbott Laboratories receives a fifth approval for its anti-inflammatory Humira, the FDA approved the biotech drug to treat yet another disease. |
The Motley Fool
November 21, 2011
Brian Orelli |
This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday? |
The Motley Fool
April 24, 2009
Brian Orelli |
The Economy Strikes Again Amgen isn't recession-proof either. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
August 26, 2009
Brian Orelli |
Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
April 23, 2008
Brian Orelli |
Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs. |
The Motley Fool
August 3, 2011
Brian Orelli |
Ignore Pfizer's Financials for Now It's the pipeline that matters. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
November 19, 2011
Luke Timmerman |
Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly. |
The Motley Fool
June 5, 2008
Brian Lawler |
Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients. |
The Motley Fool
June 12, 2008
Brian Orelli |
Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab. |
The Motley Fool
May 21, 2004
Charly Travers |
Protein Design Labs' Mixed Results Protein Design Labs' Nuvion looks like a winner, while other drugs stumble. Nuvion is in early clinical development for the treatment of severe ulcerative colitis and so far the results seem particularly compelling. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
October 2, 2007
Brian Orelli |
Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data. |
The Motley Fool
August 21, 2008
Brian Lawler |
Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment. |
The Motley Fool
April 27, 2009
Brian Orelli |
Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA. |
The Motley Fool
December 12, 2011
Brian Orelli |
FDA Irony: Less Data, Longer Review Poor Onyx Pharma. |
